Biologic & Cell Therapy Logistics
Ultra-cold and controlled-room-temperature logistics providers managing the complex chain-of-custody requirements for biologics, CAR-T therapies, and advanced medicinal products.
Market snapshot
These figures describe Healthcare & Life Sciences Logistics (10.3.4), the segment that Biologic & Cell Therapy Logistics sits within — not Biologic & Cell Therapy Logistics on its own.
Healthcare and life-sciences logistics span warehousing, transport, and distribution activities and overlap pharmaceutical distribution (profiled under Distribution & Wholesale Trade); it is not separately disclosed, so the segment is not separately sized here.
Business model & economics
Revenue model
Specialized healthcare-logistics and cold-chain fees
Key economics
- Recurring revenue
- High
- EBITDA margin
- Strong
- Capex intensity
- Moderate
recurring pharma/medical logistics
high-barrier specialty economics
Characteristics
- Regulated storage and distribution of drugs/biologics.
- Biologics and cell/gene therapy drive cold-chain demand.
- Compliance, cold-chain, and security the key capabilities.
M&A deal context
Who’s acquiring
- Healthcare-logistics specialists
- Carriers (UPS/FedEx Healthcare)
- PE-backed pharma-logistics platforms
What’s driving deals
- Biologics and specialty-pharma growth.
- Cold-chain and compliance demand.
- Specialized-logistics consolidation.
Find Biologic & Cell Therapy Logistics acquisition targets
Search Acquisera’s index for companies classified under Biologic & Cell Therapy Logistics (10.3.4.1) and build a targeted deal pipeline.
Search companies